Pathology

#Academic #Biomarkers #Drug discovery #Drug targets #Immunology #Immunology / Virology & Vaccines #Pathology #Pharmokinetics #Stem cells

Creoptix collaboration to characterise anti-SARS-CoV-2 antibodies

15 May, 2020 The Swiss next-generation bioanalytical instruments specialist announced a collaboration with Adriano Aguzzi, Professor for Neuropathology, University of Zurich, to characterise immunological responses to SARS-CoV-2 such as IgA, IgM and IgG antibodies, which signal whether an individual has been exposed to the coronavirus. The collaboration aims… Read More

#News

#Analysis #Analytical chemistry #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Genetics / genomics #Imaging #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Pathology #Pharmacology #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Target validation #Therapeutics #Translational #Translational chemistry

Innovative glycan imaging methods drive cancer biomarker discovery

Innovative glycan imaging methods drive cancer biomarker discovery By Dr Richard Drake, Dr Anand Mehta and Dr Peggy Angel Volume 21 Issue 2 - Spring 2020 Glycosylation accounts for the majority of post-translational modifications (PTMs) of proteins, and changes in glycosylation are known to play a key role in disease… Read More

#Exclusive Content

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Medicinal chemistry #Microfluidics #Molecular medicine #Pathology #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Toxicology

Optimising Phenotypic Screening – Single-cell analysis versus 3D multicell analysis

Optimising Phenotypic Screening - Single-cell analysis versus 3D multicell analysis By Dr Richard M. Eglen In light of the high failure rate of compounds when they are subjected to clinical testing, we are seeing a renaissance in phenotypic screening in drug discovery. However, most phenotypic screening is based on the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Microbiology #Nanomedicine / nanotechnology #Organic chemistry #Pathology #Precision medicine #Preclinical #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

2030 Life Sciences and Health in the Digital Age (Part 1)

2030 Life Sciences and Health in the Digital Age (Part 1) By Dr Steve Arlington and John Wise One of the key ways in which The Pistoia Alliance works with its members is to help them not just deal with the problems of today, but also to look ahead, to… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Orphan drugs #Pathology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation

Fail Early, Fail Fast – A phenotypic rescue approach

Fail Early, Fail Fast - A phenotypic rescue approach By Dr Anne-Marie Zuurmond, et al. New disease targets frequently emerge in literature, but the thorough target validation required to consider these targets for a drug discovery programme is often lacking. In pharmacological or genetic perturbation studies using complex biological assays,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene editing #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Medicinal chemistry #Molecular medicine #Oncology #Organic chemistry #Pathology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics

Automating Automation – How close are we to Artificial Intelligence impact?

Automating Automation - How close are we to Artificial Intelligence impact? By Dr Michael A. Tarselli, Dr Yohann Potier and Dr Alan E. Fletcher In terms of consistency, repeatability, known errors and sheer volume, there exists perhaps no better collection of data for computer learning than that emerging from automated… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Bioengineering #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #Genetics / genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Organic chemistry #Pathology #Pharmacology #Pharmokinetics #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Systems Pharmacology: When multi-targeting is advantageous

Systems Pharmacology: When multi-targeting is advantageous By Dr Kirkwood A. Pritchard Jr, Dr Dustin P. Martin and Dr Stephen Naylor The safety and efficacy of therapeutic drugs still requires improvement. In part this is due to the promiscuity of individual drugs, which on average can interact with an estimated 6-28… Read More

#Archive

Organoids
#Academic #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Pathology #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics

The Growth of Organoids in Cancer Drug Discovery

The Growth of Organoids in Cancer Drug Discovery By Dr J. Mark Treherne, et al., Will the automated expansion of organoids help improve the productivity of cancer drug discovery? Increasingly, complex cell-based assays and tissues are routinely used as part of cancer drug discovery. However, conventional monolayer or suspension cultures… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Business #Drug development #Drug discovery #Drug targets #High Content Screening #Pathology #Pharmacology #Preclinical #Regulatory #RNA #System biology #Systems biology #Toxicology #Translational #Translational chemistry

Beyond SEND: Leveraging non-clinical data to drive translational research forward

Beyond SEND: Leveraging non-clinical data to drive translational research forward By Katherine Briggs, et al., This article will discuss some of the potential use cases that Standard for Exchange of Nonclinical Data (SEND), datasets can support. Both to advance translational research across multiple research sites and also to drive efficiencies… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High throughput screening #Imaging #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Organic chemistry #Pathology #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #Target validation #Therapeutics #Toxicology

Increasing Drug Discovery Success With 3D Cell Culture Systems

Increasing Drug Discovery Success With 3D Cell Culture Systems By Dr Richard M. Eglen, Dr Feng Li and Dr Tony Frutos Drug candidates often fail in the clinic for two reasons: they lack efficacy or possess an adverse toxicity profile. These failures can come at a high cost, especially when… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biochemistry #Bioengineering #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genetics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Oncology #Organic chemistry #Pathology #PCR #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Cutting-edge technologies meet traditional paradigms in assay development

The Future Of Drug Discovery - Cutting-edge technologies meet traditional paradigms in assay development By Dr Roger Bosse With more than 1,500 drugs approved by the Food and Drug Administration (FDA) on the market, the easiest disease targets are already covered (1). Today’s scientists are challenged to find new compounds,… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene therapy #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Molecular medicine #Organic chemistry #Orphan drugs #Patent Law #Pathology #Pharmacogenomics #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Disruptive Approaches To Accelerate Drug Discovery and Development (Part 2)

Disruptive Approaches To Accelerate Drug Discovery and Development (Part 2) By Dr Anton Fliri, et al. Part 2: Emergent intelligence, a new paradigm for drug discovery. (You can read part 1 of disruptive approaches to accelerate drug discovery and development linked here.) The staggering clinical trial failure rate of experimental… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biobanking #Biomarkers #Business #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomics #Genomics #Lead discovery #Molecular medicine #Oncology #Pathology #Precision medicine #Regulatory #RNA #Screening #Sequencing

The Use of Next-Generation Sequencing in Drug Development

The Use of Next-Generation Sequencing in Drug Development By Keith Nangle & Mike Furness This article summarises some of the technical and regulatory challenges posed by next-generation sequencing technologies and the efforts being made to address them. Next-generation sequencing (NGS) has moved from the realm of research into those of… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Animal models #Biologics / Biotechnology #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene editing #Immunology #Lead discovery #Microbiome #Oncology #Pathology #Pharmacology #Preclinical #RNA #Stem cells #System biology #Systems biology #Target validation

How The B6 Mouse Strain is Revolutionising Drug Discovery

How The B6 Mouse Strain is Revolutionising Drug Discovery By Dr Philip Dube Inbred mice are critical tools in biomedical research and one particular strain, known as C57BL/6 (Black 6 or B6, for short), is rapidly becoming the standard model for many applications and revolutionising modern research. Understanding the B6… Read More

#Archive

#Analysis #Animal models #Assay development optimisation & technology #Biologics / Biotechnology #Biomarkers #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Oncology #Pathology #Pharmokinetics #Preclinical #Regulatory #RNA #Stem cells #Target validation #Toxicology

The Rise of Immunotherapies – Strategies to Accelerate Their Advance Into Clinical Trials

The Rise of Immunotherapies - Strategies to Accelerate Their Advance Into Clinical Trials By Edward Cribb The striking rise of immunotherapies in the past decade has had a transformative effect on the prospects for the treatment of patients with cancer. Also referred to as biologic therapies, immunotherapies are a new… Read More

#Archive

#Automation / robotics #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #High throughput screening #Lead discovery #Oncology #Organic chemistry #Pathology #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

The Importance of Heterocyclic Compounds in Anti-Cancer Drug Design

The Importance of Heterocyclic Compounds in Anti-Cancer Drug Design By Simon Pearce Heterocycles are key structural components of many of the anti-cancer drugs available on the market today. Indeed, of the novel molecular anti-cancer agents approved by the FDA between 2010 and 2015, almost two-thirds contained heterocyclic rings within their… Read More

#Archive